Skip to content
value.today

RedHill Biopharma Ltd.

🇮🇱 Tel Aviv, Israel, IsraelPharmaceuticalsFounded 2009
Total raised
$3 M
1 round on record
Latest round
$3 M
Dec 2013
First round on record
Dec 2013
Today
Went public
See the company page

RedHill Biopharma Ltd. is listed today as Redhill Biopharma: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of RedHill Biopharma Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$10 MPrivate placement after listing$10 to $50 million

RedHill Biopharma Ltd.: Private sale, Jan 2024

Investors in this round

5 investors had bought by the notice of Feb 5, 2024: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$600,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi Frish · Executive Officer
  • Dror Ben-Asher · Executive Officer, Director
  • Gilead Raday · Executive Officer
  • Guy Goldberg · Executive Officer
  • Razi Ingber · Executive Officer
  • Reza Fathi · Executive Officer
  • Rick Scruggs · Executive Officer, Director
  • Alla Felder · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Ofer Tsimchi · Director
  • Shmuel Cabilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, IL, NY, TX

Remarks in the notice

  • On fees: “The placement agent (or its designees) also received warrants to purchase up to 600,000 ADSs of the Company, at an exercise price of $1.00 per ADS under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.”
  • On the amounts: “"This Form D is being filed in connection with the issuance of warrants to purchase up to 10,000,000 American Depositary Shares (""ADSs"") at an exercise price of $1.00 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01, of the Company"”

Signed by Razi Ingber, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 5, 2024. Read the notice at the SEC.

equity, optionsSEC
Sep 2023$4 MPrivate placement after listing$2 to $10 million

RedHill Biopharma Ltd.: Private sale, Sep 2023

Investors in this round

3 investors had bought by the notice of Oct 12, 2023: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
$151,643
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi Frish · Executive Officer
  • Dror Ben-Asher · Executive Officer, Director
  • Gilead Raday · Executive Officer
  • Guy Goldberg · Executive Officer
  • Razi ingber · Executive Officer
  • Reza Fathi · Executive Officer
  • Rick Scruggs · Executive Officer, Director
  • Alla Felder · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Ofer Tsimchi · Director
  • Shmuel Cabilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “The placement agent (or its designees) also received warrants to purchase up to 258,115 ADSs of the Company at an exercise price of $0.5875 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”
  • On the amounts: “"This Form D is being filed in connection with the issuance of warrants to purchase up to 8,603,846 American Depositary Shares (""ADSs"") at an exercise price of $0.47 per ADS, each ASD representing 400 ordinary shares, par value NIS 0.01, of the Company."”

Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2023$3 MPrivate placement after listing$2 to $10 million

RedHill Biopharma Ltd.: Private sale, Jul 2023

Investors in this round

1 investor had bought by the notice of Aug 7, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
$283,695
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi Frish · Executive Officer
  • Dror Ben-Asher · Executive Officer, Director
  • Gilead Raday · Executive Officer
  • Guy Goldberg · Executive Officer
  • Razi ingber · Executive Officer
  • Reza Fathi · Executive Officer
  • Alla Felder · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Ofer Tsimchi · Director
  • Rick Scruggs · Director
  • Shmuel Cabilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “The placement agent (or its designees) also received warrants to purchase 168,115 American Depositary Shares at an exercise price of $1.6875 per ADS,each representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”
  • On the amounts: “This Form D is being filed in connection with the issuance of warrants to purchase up to 1,500,000 ADSs an exercise price of $1.80 per ADS, with each ADS each representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.”

Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 7, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$5 MPrivate placement after listing$2 to $10 million

RedHill Biopharma Ltd.: Private sale, Nov 2021

Investors in this round

1 investor had bought by the notice of Nov 22, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
$5,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
$200,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi Frish · Executive Officer
  • Dror Ben-Asher · Executive Officer, Director
  • Gilead Raday · Executive Officer
  • Guy Goldberg · Executive Officer
  • June Almenoff · Executive Officer
  • Micha Ben Chorin · Executive Officer
  • Reza Fathi · Executive Officer
  • Rick Scruggs · Executive Officer, Director
  • Alla Felder · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Ofer Tsimchi · Director
  • Shmuel Cabilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New JerseySold in no state named, and outside the US
  • Nexpedia Holdings Co., Ltd · Seoul, Korea, Republic OfSold in no state named, and outside the US

Signed by Dror Ben-Asher, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 22, 2021. Read the notice at the SEC.

equitySEC
Oct 2019$48 MPrivate placement after listing$10 to $50 million

RedHill Biopharma Ltd.: Private sale, Oct 2019

Investors in this round

2 investors had bought by the notice of Nov 6, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $48 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi D Frish · Executive Officer
  • Dror Ben-Asher · Executive Officer, Director
  • Gilead D Raday · Executive Officer
  • Guy D Goldberg · Executive Officer
  • June D Almenoff · Executive Officer
  • Micha D Ben Chorin · Executive Officer
  • Reza D Fathi · Executive Officer
  • Rick D Scruggs · Executive Officer, Director
  • Alla D Felder · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Nicolas D Weinstein · Director
  • Ofer Tsimchi · Director
  • Shmuel Cabilly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “A portion of the ADSs were issued at an agreed value of $12 million, as an upfront payment for rights granted to the issuer under an exclusive license agreement”

Signed by Micha Ben Chorin, Cfo. Source: SEC Form D, newest notice filed Nov 6, 2019. Read the notice at the SEC.

equitySEC
Dec 2013$3 MNo. 1$2 to $10 million

RedHill Biopharma Ltd.: Raise no. 1, Dec 2013

Investors in this round

1 investor had bought by the notice of Jan 15, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$175,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Israel

People named in the notice

  • Adi Frish · Executive Officer · Senior Vice President Business Development and Licensing
  • Dror Ben Asher · Executive Officer, Director · CEO and Chairman of the Board of Directors
  • Gilead Raday · Executive Officer · Senior Vice President Research and Development
  • Guy Goldberg · Executive Officer · Chief Business Officer
  • Ori Shilo · Executive Officer, Director · Deputy Chief Executive Officer Finance and Operations and Director
  • Reza Fathi · Executive Officer · Senior Vice President Research and Development
  • Uri Hananel Aharon · Executive Officer · Chief Accounting Officer
  • Aliza Rotbard · Director · External Director
  • Dan Suesskind · Director
  • Eric Swenden · Director
  • Kenneth Reed · Director
  • Ofer Tsimchi · Director · External Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · New York, New YorkSold in NY
  • Stifel, Nicolaus & Company, Incorporated (CRD 793) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Final amount being negotiated and not yet determined.”

Signed by Ori Shilo, Deputy CEO Finance and Operations and Director. Source: SEC Form D, newest notice filed Jan 15, 2014. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • RedHill Biopharma Ltd. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Feb 2024).

    SEC Form D (revenue range) · Feb 2024

  • Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2019; revenue between $25 million and $100 million in 2021; revenue between $25 million and $100 million in 2023; revenue between $5 million and $25 million in 2024.

    SEC Form D (revenue range) · Feb 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2024

Products and services#

No products or services of RedHill Biopharma Ltd. are on record.

Investors#

No investor of RedHill Biopharma Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by RedHill Biopharma Ltd.
NameRoleNamed in
Adi FrishExecutive officerFeb 2024
Dror Ben-AsherExecutive officerFeb 2024
Gilead RadayExecutive officerFeb 2024
Guy GoldbergExecutive officerFeb 2024
Razi IngberExecutive officerFeb 2024
Reza FathiExecutive officerFeb 2024
Rick ScruggsExecutive officerFeb 2024
Razi ingberExecutive officerOct 2023
June AlmenoffExecutive officerNov 2021
Micha Ben ChorinExecutive officerNov 2021
Adi D FrishExecutive officerNov 2019
Gilead D RadayExecutive officerNov 2019
Guy D GoldbergExecutive officerNov 2019
June D AlmenoffExecutive officerNov 2019
Micha D Ben ChorinExecutive officerNov 2019
Reza D FathiExecutive officerNov 2019
Rick D ScruggsExecutive officerNov 2019
Dror Ben AsherCEO and Chairman of the Board of DirectorsJan 2014
Ori ShiloDeputy Chief Executive Officer Finance and Operations and DirectorJan 2014
Uri Hananel AharonChief Accounting OfficerJan 2014
Alla FelderDirectorFeb 2024
Dror Ben-AsherDirectorFeb 2024
Eric SwendenDirectorFeb 2024
Kenneth ReedDirectorFeb 2024
Ofer TsimchiDirectorFeb 2024
Rick ScruggsDirectorFeb 2024
Shmuel CabillyDirectorFeb 2024
Alla D FelderDirectorNov 2019
Nicolas D WeinsteinDirectorNov 2019
Rick D ScruggsDirectorNov 2019
Aliza RotbardExternal DirectorJan 2014
Dan SuesskindDirectorJan 2014
Dror Ben AsherCEO and Chairman of the Board of DirectorsJan 2014
Ori ShiloDeputy Chief Executive Officer Finance and Operations and DirectorJan 2014

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.